Klinische Farmacologie & Klinische Farmacie

Medicine & Life Sciences

1. Acute Kidney Injury 15%
2. Aldosterone 18%
3. Ambulances 24%
4. Ambulatory Blood Pressure Monitoring 35%
5. Aneurysm 11%
6. Angiotensin Type 2 Receptor 25%
7. Anticoagulants 87%
8. Antihypertensive Agents 20%
9. apixaban 17%
10. ATP Binding Cassette Transporter, Subfamily B, Member 1 12%
11. Atrial Fibrillation 53%
12. Autosomal Dominant Polycystic Kidney 15%
13. Baroreflex 12%
14. Belgium 47%
15. Blood Pressure 80%
16. Blood Vessels 21%
17. Chronic Kidney Failure 10%
18. Chronic Renal Insufficiency 19%
19. Clinical Decision Support Systems 30%
20. Cohort Studies 10%
21. Confidence Intervals 14%
22. Continuous Ambulatory Peritoneal Dialysis 11%
23. Cross-Sectional Studies 28%
24. Dabigatran 15%
25. Dialysis 29%
26. Dialysis Solutions 22%
27. Dissection 12%
28. Dopamine 33%
29. Dopamine Agonists 12%
30. Dopamine Receptors 10%
31. Drug Hypersensitivity 14%
32. Drug Interactions 41%
33. Drug Utilization 15%
34. Electronic Prescribing 33%
35. Enalapril 14%
36. Epinephrine 10%
37. Essential Hypertension 32%
38. Fenoldopam 64%
39. Fibromuscular Dysplasia 100%
40. gamma-Aminobutyric Acid 10%
41. gamma-glutamyl DOPA 11%
42. General Practitioners 14%
43. Geriatrics 24%
44. Glomerular Filtration Rate 10%
45. Guanfacine 17%
46. Hemodynamics 25%
47. Hemorrhage 11%
48. Hospitalization 10%
49. Hypertension 74%
50. Inbred SHR Rats 21%
51. Inbred WKY Rats 14%
52. Kidney 61%
53. Lithium 17%
54. Medication Reconciliation 19%
55. Meta-Analysis 30%
56. methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate 9%
57. Metoclopramide 14%
58. Mortality 10%
59. Multicenter Studies 10%
60. Nicardipine 14%
61. Nitric Oxide 11%
62. Norepinephrine 12%
63. Patient Discharge 12%
64. Perfusion 11%
65. Pharmaceutical Preparations 37%
66. Pharmaceutical Services 29%
67. Pharmaceutical Societies 11%
68. Pharmacies 23%
69. Pharmacists 82%
70. Pharmacology 12%
71. Pharmacy 15%
72. Phenotype 10%
73. Physicians 25%
74. Placebos 16%
75. Pregnant Women 14%
76. Prescriptions 24%
77. Prolactin 10%
78. Quinpirole 15%
79. Registries 14%
80. Renal Artery 15%
81. Renal Artery Obstruction 9%
82. Renal Circulation 18%
83. Renal Dialysis 28%
84. Risk Assessment 11%
85. Rivaroxaban 15%
86. Safety 15%
87. SCH 23390 10%
88. Sodium 20%
89. Software 11%
90. Solitary Nucleus 13%
91. Stroke 36%
92. Superinfection 10%
93. Systematic Reviews 37%
94. Telemedicine 27%
95. Therapeutics 21%
96. Tolvaptan 17%
97. University Hospitals 21%
98. Vasodilator Agents 17%
99. Vitamin K 14%
100. Warfarin 14%